Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

BACKGROUND: Some patients with severe asthma have recurrent asthma exacerbations associated with eosinophilic airway inflammation. Early studies suggest that inhibition of eosinophilic airway inflammation with mepolizumab-a monoclonal antibody against interleukin 5-is associated with a reduced risk...

Detaylı Bibliyografya
Asıl Yazarlar:	Pavord, I, Korn, S, Howarth, P, Bleecker, E, Buhl, R, Keene, O, Ortega, H, Chanez, P
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2012

Benzer Materyaller

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Yazar:: Ortega, H, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Mepolizumab treatment in patients with severe eosinophilic asthma.
Yazar:: Ortega, H, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
Yazar:: Yancey, S, ve diğerleri
Baskı/Yayın Bilgisi: (2016)

Glucocorticoids and mepolizumab in eosinophilic asthma.
Yazar:: Bel, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Mepolizumab in refractory eosinophilic asthma.
Yazar:: Pavord, I, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Yazar:: Bel, E, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
Yazar:: Shrimanker, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Yazar:: Howell, I, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Mepolizumab, quality of life, and severe eosinophilic asthma.
Yazar:: Pavord, I
Baskı/Yayın Bilgisi: (2017)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Yazar:: Imran Howell, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
Yazar:: Haldar, P, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Yazar:: Steven W. Yancey, ve diğerleri
Baskı/Yayın Bilgisi: (2019-09-01)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
Yazar:: Gunsoy, N, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
Yazar:: Moran, AM, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
Yazar:: Wechsler, M, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
Yazar:: Pavord, I, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
Yazar:: Shrimanker, R, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Biomarkers for severe eosinophilic asthma.
Yazar:: Yancey, S, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Mepolizumab for eosinophilic COPD
Yazar:: Sciurba, F, ve diğerleri
Baskı/Yayın Bilgisi: (2018)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
Yazar:: Shrimanker, R, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies
Yazar:: Mi-Kyeong Kim, ve diğerleri
Baskı/Yayın Bilgisi: (2021-03-01)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
Yazar:: Ian D. Pavord, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

Response to mepolizumab treatment is sustained across 4-weekly dosing periods
Yazar:: Ian D. Pavord, ve diğerleri
Baskı/Yayın Bilgisi: (2020-09-01)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Yazar:: Ian Pavord, ve diğerleri
Baskı/Yayın Bilgisi: (2023-04-01)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
Yazar:: Menzella F, ve diğerleri
Baskı/Yayın Bilgisi: (2016-06-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
Yazar:: Terufumi Shimoda, ve diğerleri
Baskı/Yayın Bilgisi: (2017-07-01)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Yazar:: Haldar P
Baskı/Yayın Bilgisi: (2017-06-01)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
Yazar:: Kayser MZ, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
Yazar:: Moran, A, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
Yazar:: Chio Sakai, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
Yazar:: Haldar, P, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
Yazar:: Haldar, P, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Clinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in children
Yazar:: V. N. Drozdov, ve diğerleri
Baskı/Yayın Bilgisi: (2020-11-01)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
Yazar:: Takanori Numata, ve diğerleri
Baskı/Yayın Bilgisi: (2019-10-01)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
Yazar:: Haldar, P, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Yazar:: Pavord, I, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
Yazar:: Manuel David Gil-Sierra, ve diğerleri
Baskı/Yayın Bilgisi: (2019-11-01)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life
Yazar:: Diego Bagnasco, ve diğerleri
Baskı/Yayın Bilgisi: (2021-02-01)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
Yazar:: Prazma CM, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
Yazar:: I. J. Pouliquen, ve diğerleri
Baskı/Yayın Bilgisi: (2017-11-01)